Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Innovation Center China, AstraZeneca, Shanghai, 201203, China.
Lung Cancer. 2014 May;84(2):190-5. doi: 10.1016/j.lungcan.2013.08.029. Epub 2013 Sep 8.
The atypical protein kinase C isozyme iota (PKCiota) has been proposed as an oncogene based on its transformation property and amplification identified in Caucasian non-small cell lung cancer (NSCLC) patients. Because the geography difference of some genetic aberrance such as EGFR mutations between Caucasian and Asian NSCLC patients has been identified previously, it is important to know whether the PKCiota amplification also occurs in Asian NSCLC patients.
The PKCiota gene copy number changes and protein expression in Chinese patients samples were detected by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), respectively. Logistic regression was used to assess the association of PKCiota expression with clinicopathological parameters. siRNA-mediated gene silencing was applied to demonstrate the role of PKCiota in promoting cell growth in PKCiota gene amplified and protein overexpressed cancer cells.
The result showed that PKCiota gene was amplified in 20.2% (24/119) of the tested primary tumor samples from Chinese NSCLC patients. Interestingly this gene amplification was highly enriched in squamous NSCLC patients (37.1%, 23/62). Further IHC analysis indicated that PKCiota protein was highly expressed (IHC score 2+ and 3+) in 91.6% (109/119) of Chinese NSCLC tumors. Moreover, the PKCiota gene amplification was also correlated with gender, subtype and distant metastasis. Knockdown of PKCiota gene in the PKCiota gene amplified and protein overexpressed cells led to significant growth inhibition.
Taken together, our data demonstrate that PKCiota is a potential oncogene and therapeutic target in Chinese NSCLC.
非典型蛋白激酶 C 同工酶 iota(PKCiota)已被提出作为致癌基因,基于其在白种人非小细胞肺癌(NSCLC)患者中发现的转化特性和扩增。由于之前已经确定了白种人和亚洲 NSCLC 患者之间某些遗传异常(如 EGFR 突变)的地理差异,因此了解 PKCiota 扩增是否也发生在亚洲 NSCLC 患者中非常重要。
通过荧光原位杂交(FISH)和免疫组织化学(IHC)分别检测中国患者样本中的 PKCiota 基因拷贝数变化和蛋白表达。采用逻辑回归评估 PKCiota 表达与临床病理参数的相关性。应用 siRNA 介导的基因沉默来证明 PKCiota 在促进 PKCiota 基因扩增和蛋白过表达癌细胞生长中的作用。
结果显示,在来自中国 NSCLC 患者的 20.2%(24/119)的测试原发性肿瘤样本中扩增了 PKCiota 基因。有趣的是,这种基因扩增在鳞状 NSCLC 患者中高度富集(37.1%,23/62)。进一步的 IHC 分析表明,PKCiota 蛋白在 91.6%(109/119)的中国 NSCLC 肿瘤中高度表达(IHC 评分 2+和 3+)。此外,PKCiota 基因扩增还与性别、亚型和远处转移相关。在 PKCiota 基因扩增和蛋白过表达细胞中敲低 PKCiota 基因导致明显的生长抑制。
总之,我们的数据表明 PKCiota 是中国 NSCLC 的潜在致癌基因和治疗靶点。